asa glp-1 agonist guidelines medications safe to continue before surgery in patients with diabetes and obesity How should GLP-1 receptor agonists

Management of hyperglycaemia in type 2 diabetes, 2022

The global prevalence of 537 million affected in the age group of 2079 years in 2021 will rise to 783 million in 2045, with the lowest increase in incidence in Europe (13%) and the highest in the African countries south of the Sahara (134%) ( Obesity, defined as a body mass index above 30 kg/m 2 , is also increasingly prevalent worldwide and has become a challenge to the various healthcare systems and societies

Its most critical role during GLP-1 therapy is helping to preserve lean muscle mass

The study protocol was registered in the International Prospective Register of systematic reviews PROSPERO (CRD420251002447)

Adipose lipid turnover and long-term changes in body weight

van Can, J